Tomoyasu Higashimoto

Tomoyasu Higashimoto

Auto-generated profile, based on publicly available information

Tomoyasu Higashimoto

Department of Internal Medicine, Division of Genetic Medicine University of Michigan Ann Arbor Michigan USA

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 August 2009 in Blood
Verified
Journal Article
Open access
PDF file
APAjay Perumbeti
Ajay Perumbeti
THTomoyasu Higashimoto
Tomoyasu Higashimoto
FUFabrizia Urbinati
Fabrizia Urbinati
RFRobert Franco
Robert Franco
HMHerbert J. Meiselman
Herbert J. Meiselman
PMPunam Malik
Punam Malik
We show that lentiviral delivery of human γ-globin gene under β-globin regulatory control elements in hematopoietic stem cells (HSCs) results in sufficient postnatal fetal hemoglobin (HbF) expression to correct sickle cell anemia (SCA) in the Berkeley “humanized” sickle mouse. Upon de-escalating the amount of transduced HSCs in transplant recipients, using reduced-intensity conditioning and varying gene transfer efficiency and vector copy number, we assessed critical parameters needed for correction. A systematic quantification of functional and hematologic red blood cell (RBC) indices, organ pathology, and life span was used to determine the minimal amount of HbF, F cells, HbF/F-cell, and gene-modified HSCs required for correcting the sickle phenotype. We show that long-term amelioration of disease occurred (1) when HbF exceeded 10%, F cells constituted two-thirds of the circulating RBCs, and HbF/F cell was one-third of the total hemoglobin in sickle RBCs; and (2) when approximately 20% gene-modified HSCs repopulated the marrow. Moreover, we show a novel model using reduced-intensity conditioning to determine genetically corrected HSC threshold that corrects a hematopoietic disease. These studies provide a strong preclinical model for what it would take to genetically correct SCA and are a foundation for the use of this vector in a human clinical trial.

14 September 2004 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
QWQingxue Wang
Qingxue Wang
MIMasamichi Ito
Masamichi Ito
KAKathleen Adams
Kathleen Adams
BLB U.K. Li
B U.K. Li
TKThomas Klopstock
Thomas Klopstock
RBRichard G. Boles
Richard G. Boles

28 June 2007 in Gene Therapy
Verified
Journal Article
Open access
PDF file
THT Higashimoto
T Higashimoto
FUF Urbinati
F Urbinati
APA Perumbeti
A Perumbeti
GJG Jiang
G Jiang
AZA Zarzuela
A Zarzuela
PMP Malik
P Malik
The woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) increases transgene expression from a variety of viral vectors, although the precise mechanism is not known. WPRE is most effective when placed downstream of the transgene, proximal to the polyadenylation signal. We hypothesized that WPRE likely reduces viral mRNA readthrough transcription by improving transcript termination, which in turn would increase viral titers and expression. Using a Cre-lox-mediated plasmid-based assay, we found significant readthrough transcription from γ-retroviral vector (RV) long terminal repeat (wt RV-LTR) and RV LTR with a self-inactivating deletion (SIN RV-LTR). WPRE, when placed upstream of the RV LTRs, significantly reduced readthrough transcription. Readthrough, present at much lower levels with the SIN HIV-1 LV-LTR, was also reduced with WPRE. When placed in RV vectors, WPRE increased total RV genomic mRNA; and increased viral titers from transiently transfected 293T cells and stable PG13 producer cells by 7- to 15-fold. The mechanism of increased titers and expression was not due to increased nuclear mRNA export, increased rate of viral transcription or a significant increase in viral mRNA half-life. Our results showed that WPRE improved vector genomic transcript termination to increase titers and expression from RVs.

8 July 2010 in Blood
Verified
Journal Article
Closed access
PDF file
NSNambirajan Sundaram
Nambirajan Sundaram
ATAnitaben Tailor
Anitaben Tailor
LMLaurel Mendelsohn
Laurel Mendelsohn
JWJanaka Wansapura
Janaka Wansapura
XWXunde Wang
Xunde Wang
PMPunam Malik
Punam Malik
Pulmonary hypertension is associated with reduced nitric oxide bioavailability and early mortality in sickle cell disease (SCD). We previously demonstrated that placenta growth factor (PlGF), an angiogenic factor produced by erythroid cells, induces hypoxia-independent expression of the pulmonary vasoconstrictor endothelin-1 in pulmonary endothelial cells. Using a lentivirus vector, we simulated erythroid expression of PlGF in normal mice up to the levels seen in sickle mice. Consequently, endothelin-1 production increased, right ventricle pressures increased, and right ventricle hypertrophy and pulmonary changes occurred in the mice within 8 weeks. These findings were corroborated in 123 patients with SCD, in whom plasma PlGF levels were significantly associated with anemia, endothelin-1, and tricuspid regurgitant velocity; the latter is reflective of peak pulmonary artery pressure. These results illuminate a novel mechanistic pathway linking hemolysis and erythroid hyperplasia to increased PlGF, endothelin-1, and pulmonary hypertension in SCD, and suggest that strategies that block PlGF signaling may be therapeutically beneficial. This trial was registered at http://clinicaltrials.gov as #NCT00011648.

1 November 2009 in Molecular Therapy
Verified
Journal Article
Open access
PDF file
PAParitha I Arumugam
Paritha I Arumugam
THTomoyasu Higashimoto
Tomoyasu Higashimoto
FUFabrizia Urbinati
Fabrizia Urbinati
UMUte Modlich
Ute Modlich
SNShawna Nestheide
Shawna Nestheide
PMPunam Malik
Punam Malik
Insertional mutagenesis by long terminal repeat (LTR) enhancers in γ-retrovirus-based vectors (GVs) in clinical trials has prompted deeper investigations into vector genotoxicity. Experimentally, self-inactivating (SIN) lentivirus vectors (LVs) and GV containing internal promoters/enhancers show reduced genotoxicity, although strong ubiquitously-active enhancers dysregulate genes independent of vector type/design. Herein, we explored the genotoxicity of β-globin (BG) locus control region (LCR), a strong long-range lineage-specific-enhancer, with/without insulator (Ins) elements in LV using primary hematopoietic progenitors to generate in vitro immortalization (IVIM) assay mutants. LCR-containing LV had ~200-fold lower transforming potential, compared to the conventional GV. The LCR perturbed expression of few genes in a 300 kilobase (kb) proviral vicinity but no upregulation of genes associated with cancer, including an erythroid-specific transcription factor occurred. A further twofold reduction in transforming activity was observed with insulated LCR-containing LV. Our data indicate that toxicology studies of LCR-containing LV in mice will likely not yield any insertional oncogenesis with the numbers of animals that can be practically studied.

1 September 2009 in Molecular Therapy
Verified
Journal Article
Open access
FUFabrizia Urbinati
Fabrizia Urbinati
PAParitha Arumugam
Paritha Arumugam
THTomoyasu Higashimoto
Tomoyasu Higashimoto
APAnil Perumbeti
Anil Perumbeti
KMKyle Mitts
Kyle Mitts
PMPunam Malik
Punam Malik
Self-inactivating (SIN) lentiviruses flanked by the 1.2-kb chicken hypersensitive site-4 (cHS4) insulator element provide consistent, improved expression of transgenes, but have significantly lower titers. The mechanism by which this occurs is unknown. Lengthening the lentiviral (LV) vector transgene cassette by an additional 1.2 kb by an internal cassette caused no further reduction in titers. However, when cHS4 sequences or inert DNA spacers of increasing size were placed in the 3′-long terminal repeat (LTR), infectious titers decreased proportional to the length of the insert. The stage of vector life cycle affected by vectors carrying the large cHS4 3′LTR insert was compared to a control vector: there was no increase in read-through transcription with insertion of the 1.2-kb cHS4 in the 3′LTR. Equal amount of full-length viral mRNA was produced in packaging cells and viral assembly/packaging was unaffected, resulting in comparable amounts of intact vector particles produced by either vectors. However, LV vectors carrying cHS4 in the 3′LTR were inefficiently processed following target-cell entry, with reduced reverse transcription and integration efficiency, and hence lower transduction titers. Therefore, vectors with large insertions in the 3′LTR are transcribed and packaged efficiently, but the LTR insert hinders viral-RNA (vRNA) processing and transduction of target cells. These studies have important implications in design of integrating vectors.